Durect corporation announces publication of larsucosterol phase 2b results in nejm evidence

The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the company's planned phase 3 trial cupertino, calif. , jan. 28, 2025 /prnewswire/ -- durect corporation (nasdaq: drrx) today announced the publication of a peer-reviewed article on the ahfirm trial data in nejm evidence.
DRRX Ratings Summary
DRRX Quant Ranking